Can switching drugs outsmart advanced breast cancer? new trial aims to find out
Disease control
Recruiting now
This study tests two antibody drug conjugates (datopotamab deruxtecan and trastuzumab deruxtecan) given one after the other in people with HER2-negative metastatic breast cancer that has worsened after prior treatment. The goal is to see if this sequence can shrink tumors or slow…
Phase: PHASE2 • Sponsor: Ana C Garrido-Castro, MD • Aim: Disease control
Last updated May 18, 2026 12:04 UTC